Lerner Lorena Raquel 4

What Happened

• Lorena Raquel Lerner, Chief Science Officer of Keros Therapeutics (KROS), sold 3,873 shares on 2026-02-18. The reported weighted-average sale price was $16.35 per share for total proceeds of approximately $63,324. This was a sale (not a purchase) and appears to have been executed to cover tax withholding related to vested restricted stock units.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (appears timely within the two-business-day window).
• Sale type/code: Open market or private sale (S).
• Shares sold: 3,873; weighted-average price reported: $16.35; total proceeds: ~$63,324.
• Price range: shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 (filing includes a footnote offering to provide per-price breakdown on request).
• Footnote: Issuer’s "sell-to-cover" policy — these sales were automatic to satisfy tax withholding on RSU vesting and were not at the reporting person’s discretion.
• Shares owned after transaction: Not specified in the Form 4 filing.

Context

• This transaction is a routine sell-to-cover tied to RSU vesting (tax withholding), which is common and not necessarily an indicator of the insider’s view on the company’s prospects. No 10b5-1 plan or unusual trading pattern is mentioned in the filing.